Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Follow the Money: Why the Democrats Won't Kill Private Medicare Plans

This article was originally published in RPM Report

Executive Summary

Democrats are taking over Congress with a strong distaste for high CMS payments to PDP and MA plans. Big cuts to those payments would be really bad news to the system, but the cuts are unlikely. The program has buitlt a stable base during its first year -- enough to withstand a big blow of rhetorical threats.

You may also be interested in...



No Sale: The Democratic Congress Tries to Roll Back Enrollment in Medicare Advantage

Price negotiation has stalled, but the Democratic Congress still wants to put its mark on Medicare Part D. There are plenty of levers to pull that could subtly but profoundly reshape the evolution of this critical new pharma market. One example: cracking down on marketing "abuses" by private Medicare plans.

No Sale: The Democratic Congress Tries to Roll Back Enrollment in Medicare Advantage

Price negotiation has stalled, but the Democratic Congress still wants to put its mark on Medicare Part D. There are plenty of levers to pull that could subtly but profoundly reshape the evolution of this critical new pharma market. One example: cracking down on marketing "abuses" by private Medicare plans.

Making Part D Stick: Lessons From the First Year of Medicare Rx

Medicare beneficiaries stuck with their Part D plans heading into 2007. That gives insurers more leverage in price negotiations with big pharma. It also means Part D may be more likely to stick around despite critics in the Democratic Congress.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS079996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel